OTCMKTS:IMUN Immune Therapeutics (IMUN) Stock Price, News & Analysis → CBOE shift unlocks new weekend income strategy (From DTI) (Ad) Free IMUN Stock Alerts $0.09 0.00 (0.00%) (As of 10/19/2023) Add Compare Share Share Today's Range$0.09▼$0.0950-Day Range$0.09▼$0.0952-Week Range$0.07▼$1.30Volume12 shsAverage Volume15,246 shsMarket Capitalization$7.78 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartFinancialsHeadlinesSEC FilingsShort Interest Get Immune Therapeutics alerts: Email Address Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Immune Therapeutics Stock (OTCMKTS:IMUN)Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is based in Winter Park, Florida.Read More IMUN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IMUN Stock News HeadlinesMarch 25, 2024 | usnews.comRussian Security Failure? Kremlin Says No Country Is Immune to TerrorismMarch 21, 2024 | msn.comScientists shed light on key immune regulators involved in Alzheimer’s and other disorders of lipid-rich tissuesMarch 28, 2024 | DTI (Ad)my top trade on these 9 tickersThis indicator is uniquely designed to spot the most significant moves in the top stocks out there (and according to our backtesting it has historically nailed these moves with a stunning 90% accuracy). Now, most folks have been saying NVDA is way overbought or overpriced. They didn’t want to “buy at the top” 6 weeks ago… Or again 4 weeks ago… or again 2 weeks ago… And it’s not their fault! That’s what all the talking heads were saying too. But the Apex Indicator would have clearly shown that these were opportunities to buy. And, sure enough, Nvidia slammed through the recommended targets again and again.March 19, 2024 | msn.comEmpty 'backpacks' attached to neutrophils activate the immune system against cancerMarch 19, 2024 | msn.comNew drug candidates could 'unmask' HIV-infected cells that evade the immune systemMarch 18, 2024 | msn.comNew Medical Breakthrough: Innovative Application of Immune ProteinMarch 11, 2024 | msn.comRevolutionary Breakthrough: Unraveling the Role of an Immune Protein with Therapeutic PotentialMarch 7, 2024 | msn.comA Key to Immunity Unlocked: How a Novel Discovery of an Immune Protein Opens Up New Possibilities for HealingMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 4, 2024 | msn.comImmune Protein’s Novel Use: A Leap Forward in Medical TreatmentMarch 4, 2024 | msn.comImmune Protein’s Newly Found Role May Pave Way for Groundbreaking Medical AdvancesFebruary 26, 2024 | msn.comA groundbreaking discovery: the function of an immune protein, opening up new possibilities for revolutionary therapiesFebruary 22, 2024 | msn.comImmune cell receptor provides promising immunotherapy targetFebruary 22, 2024 | msn.comHow an immune protein works: a breakthrough finding with potential for radical therapiesFebruary 19, 2024 | msn.comScientists Have Made A Groundbreaking Discovery – A New Application For An Immune Protein That Could Revolutionize TreatmentsFebruary 19, 2024 | msn.comResearchers Discovered A New Function For An Immune Protein That May Result In Revolutionary TreatmentsFebruary 16, 2024 | finance.yahoo.comSmart Immune appoints key new members to its Board of DirectorsFebruary 14, 2024 | msn.comAlzheimer's Linked to Epigenetic Changes in Immune Cells Outside The BrainFebruary 13, 2024 | msn.comScientists Have Made A Groundbreaking Discovery By Finding A New Purpose For An Immune Protein, which Could Lead To Groundbreaking TreatmentsFebruary 8, 2024 | msn.comScientists have made a groundbreaking discovery about the function of an immune protein, opening up new possibilities for revolutionary therapiesFebruary 6, 2024 | msn.comTrump Is Not Immune From Prosecution in His 2020 Election Interference Case, US Appeals Court SaysFebruary 6, 2024 | msn.comScientists Found A New Role For An Immune Protein, Which Could Lead To Groundbreaking TherapiesFebruary 5, 2024 | msn.comScientists Have Stumbled Upon A Groundbreaking Discovery - A New Application For An Immune Protein That Could Revolutionize TreatmentsJanuary 31, 2024 | msn.comScientists Have Discovered A New Use For An Immune Protein, Which Could Lead To Groundbreaking TreatmentsJanuary 30, 2024 | msn.comEvolutionary origin of mysterious immune system molecule in humans revealedJanuary 29, 2024 | usnews.comStudy Looks at COVID Threat to Folks With Weakened Immune SystemsJanuary 26, 2024 | msn.comScientists Have Discovered A New Role For An Immune Protein, Which Could Lead To Groundbreaking TherapiesSee More Headlines Receive IMUN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Immune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolOTCMKTS:IMUN CUSIPN/A CIK1559356 Webwww.immunetherapeutics.com Phone(888) 613-8802FaxN/AEmployees2Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,540,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-544.75% Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-3.10Miscellaneous Outstanding Shares83,660,000Free Float41,335,000Market Cap$7.78 million OptionableNot Optionable Beta0.46 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Kelly O'Brien Wilson (Age 51)Interim CEO, COO & Pres Comp: $53.83kMs. Noreen M. Griffin (Age 70)Exec. VP of Bus. Devel. & CEO Mr. Glen A. Farmer M.B.A. (Age 54)Chief Financial Officer Ms. Cynthia Douglas (Age 50)Company Sec. Dr. Joseph M. Fortunak (Age 68)VP of Global R&D and Chemical Devel. Key CompetitorsHillstream BioPharmaNASDAQ:HILSCan-Fite BioPharmaNYSE:CANFAyala PharmaceuticalsNASDAQ:ADXSProtagenic TherapeuticsNASDAQ:PTIXPasithea TherapeuticsNASDAQ:KTTAView All Competitors IMUN Stock Analysis - Frequently Asked Questions How have IMUN shares performed in 2024? Immune Therapeutics' stock was trading at $0.0930 at the beginning of the year. Since then, IMUN shares have increased by 0.0% and is now trading at $0.0930. View the best growth stocks for 2024 here. What other stocks do shareholders of Immune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Alexion Pharmaceuticals (ALXN), AK Steel (AKS), Galiano Gold (AKG), Agritek (AGTK), Agenus (AGEN), Affymetrix (AFFX), Advanced Disposal Services (ADSW), Adamis Pharmaceuticals (ADMP) and Analog Devices (ADI). How do I buy shares of Immune Therapeutics? Shares of IMUN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:IMUN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immune Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.